Please assess the completion status of the following clinical trial:

Trial Title: Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned bronchoscopy in relation to work-up after hemoptysis or other symptom leading to bronchoscopy~* Informed written consent~* Performance status 0-1~* Ct scan of thorax without suspicion of malignancy~* Weight t ≥ 60 og ≤ 130 kg~* Male gender or female gender in postmenopausal state defined by amenorrhea in more than 12 months.~Exclusion Criteria:~* Voriconazole treatment up to one week before inclusion~* Se-creatinin≥ 100 uM~* ALAT ≥ 70 U/l~* QT-interval \> 480 ms~* Allergic reaction to voriconazole or constituents in Vfend~* Allergic reaction to other azoles~* Ischemic Heart disease, Heart failure or uncontrolled hypertension~* Treatment with statins or omeprazole, which cannot be paused for three days during voriconazole exposure~* Treatment with Efavirenz, rifabutin, ritonavir, everolimus, methadon, alfentanil, fentanyl, sufentanil, oxycodone, hydrocodone, fluconazole, aztemizol, cisaprid, pimozid, quinidine, terfenadine, carbamazepine, phenobarbital, mephobarbital, ergotamine, dihydroergotamine, rifampicine, st. johns worth, everolimus, phenytoin, warfarin, phenprocoumon, acenocoumarol, benzodiazepines as midazolam, triazolam, alprazolam, sirolimus, cyclosporine, tacrolimus, ibuprofen, diclofenac,tolbutamide, glipizide, vincristine, vinblastine or other vinca alkaloids, HIV-protease Inhibitors e.g. saquinavir, amprenavir and nelfinavir, delavirdine, nivrapine and other non-nocleaoside revers transcriptase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled voriconazole (Type: EXPERIMENTAL): 12 patients inhale voriconazole 40 mg b.i.d for two days
- Oral Voriconazole (Type: ACTIVE_COMPARATOR): 12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day

Based on this trial design, predict the completion outcome and termination type (if applicable).